RESUMO
The sudden emergence of the COVID-19 pandemic brought global disruption to every aspect of society including healthcare, supply chain, the economy, and social interaction. Among the many emergent considerations were the safety and public health of the public, patients, essential workers, and healthcare professionals. In certain locations, clinical research was halted-or terminated-in deference to the immediate needs of patient care, and clinical trials focusing on the treatment and prevention of coronavirus infection were prioritized over studies focusing on other diseases. Difficult decisions were made rapidly; flexibility and reconsideration were necessary not only because the intensity and severity of infection varied over time and by locale but also because knowledge of the disease and understanding of its treatment (and prevention) grew. Here we discuss the ethical challenges in decision-making and competing ethical tensions during the pandemic in an effort to advance future preparedness.
Assuntos
COVID-19 , Estudos Clínicos como Assunto/ética , Segurança do Paciente , Humanos , Pandemias , SARS-CoV-2RESUMO
Extensive studies have ascribed a role for the central 5-HT3 receptor in the modulation of behaviour. Much of the work stems from the actions of potent and selective 5-HT3 receptor antagonists; these agents reduce mesolimbic dopamine initiated hyperactivity, release suppressed behaviour, reduce the reinforcing properties and withdrawal symptoms of drugs of abuse, enhance cognitive performance and modulate appetite. This article reviews the preclinical and clinical evidence implicating the 5-HT3 receptor in these indications and discusses the potential neurochemical mechanisms underlying the behavioural changes.
Assuntos
Comportamento/efeitos dos fármacos , Receptores de Serotonina/fisiologia , Animais , Comportamento Animal/efeitos dos fármacos , Humanos , Receptores de Serotonina/efeitos dos fármacosRESUMO
The ability of (-)N-n-propylnorapomorphine and selective D1 and D2 dopamine receptor agonists and antagonists to modify the release of [3H]dopamine, induced by potassium from the nucleus accumbens, was studied using an in vitro superfusion technique. (-)N-n-Propylnorapomorphine, in picomolar concentrations, inhibited the release of [3H]dopamine, the inhibition being antagonised by fluphenazine and the selective D2 receptor antagonist sulpiride; the selective D1 receptor antagonist SCH 23390 was ineffective. The selective D1 receptor agonist SKF 38393 and the selective D2 agonist quinpirole, both inhibited the potassium-induced release of [3H]dopamine; no synergistic effect was observed to a combined treatment with SKF 38393 and quinpirole. The effects of SKF 38393 and quinpirole were selectively antagonised by SCH 23390 and sulpiride, respectively, although both antagonists failed to modify the release of [3H]dopamine when administered alone. Receptor antagonists for other transmitter sites, e.g. noradrenaline, 5-hydroxytryptamine and acetylcholine, failed to modify potassium-induced release of [3H]dopamine, when administered alone or to prevent the inhibition of the release caused by (-)N-n-propylnorapomorphine. It is concluded that the action of dopamine agonists on both dopamine D1 and D2 receptors in the nucleus accumbens can reduce the release of [3H]dopamine in the in vitro system. Comparable actions in vivo may contribute to the ability of dopamine agonists to moderate locomotor responding.
Assuntos
Apomorfina/análogos & derivados , Dopaminérgicos/farmacologia , Dopamina/metabolismo , Núcleo Accumbens/metabolismo , Receptores Dopaminérgicos/metabolismo , Núcleos Septais/metabolismo , 2,3,4,5-Tetra-Hidro-7,8-Di-Hidroxi-1-Fenil-1H-3-Benzazepina/farmacologia , Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Animais , Apomorfina/farmacologia , Benzazepinas/farmacologia , Ergolinas/farmacologia , Feminino , Flufenazina/farmacologia , Atividade Motora/efeitos dos fármacos , Núcleo Accumbens/efeitos dos fármacos , Potássio/farmacologia , Quimpirol , Ratos , Receptores Dopaminérgicos/efeitos dos fármacos , Sulpirida/farmacologiaRESUMO
The involvement of 5-hydroxytryptamine (5-HT) with cisplatin-induced emesis in the ferret was investigated using reserpine, para-chlorophenylalanine and fenfluramine. Pretreatment with reserpine (5 mg/kg, 24 hr), fenfluramine (5 mg/kg, 4 days) or para-chlorophenylalanine (100 or 400 mg/kg, 4 days) antagonised cisplatin-induced emesis. All treatments reduced the levels of 5-HT in the area postrema and at other cerebral sites, but whilst this action was relatively selective for small doses of para-chlorophenylalanine [only modest effects on noradrenaline (NA) and no change in the content of dopamine (DA) in the area postrema], other treatments reduced levels of dopamine and noradrenaline. Data are discussed in terms of an involvement of 5-HT/catecholamines in the area postrema with the mediation of emesis induced by cisplatin.
Assuntos
Carnívoros/fisiologia , Cisplatino/antagonistas & inibidores , Fenclonina/farmacologia , Fenfluramina/farmacologia , Furões/fisiologia , Reserpina/farmacologia , Vômito/induzido quimicamente , Animais , Monoaminas Biogênicas/metabolismo , Química Encefálica/efeitos dos fármacos , Núcleo Caudado/efeitos dos fármacos , Núcleo Caudado/metabolismo , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Masculino , Neurotransmissores/metabolismo , Vômito/prevenção & controleRESUMO
The pharmacological characterisation and topographical distribution of [3H]-(S)-zacopride recognition sites in the forebrain of the rat was studied using homogenate and autoradiographic radioligand binding techniques. [3H]-(S)-Zacopride labelled a single, saturable, specific binding site (defined by 10.0 microM granisetron) in homogenates prepared from the entorhinal cortex of the rat (pKD = 9.51 +/- 0.08; Bmax = 104 +/- 7 fmol mg-1 protein; mean +/- SEM, n = 8). Pharmacological characterisation of the recognition site, within the entorhinal cortex, suggested that [3H]-(S)-zacopride selectively labelled the recognition site of the 5-HT3 receptor. Specific binding of [3H]-(S)-zacopride (defined by 1.0 microM granisetron) was differentially distributed throughout the forebrain of the rat; highest densities were located within sub-nuclei of the amygdala (cortical amygdaloid nucleus, amygdalohippocampal area, posterior medial cortical amygdaloid nucleus, posterior lateral amygdaloid nucleus), cortical areas (primary olfactory cortex, entorhinal cortex) and hippocampus. Non-specific binding was distributed homogeneously, although lower in myelinated structures. It is concluded that [3H]-(S)-zacopride selectively labels 5-HT3 receptor recognition sites within the forebrain of the rat; the topographical distribution of these sites, within the limbic nuclei, is consistent with the behavioural actions in animal models of the selective 5-HT3 receptor antagonists.
Assuntos
Benzamidas/metabolismo , Encéfalo/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes , Compostos Bicíclicos com Pontes/metabolismo , Receptores de Serotonina/metabolismo , Antagonistas da Serotonina/metabolismo , Animais , Autorradiografia , Ligação Competitiva , Feminino , Hipocampo/metabolismo , Cinética , Especificidade de Órgãos , Ratos , Ratos Endogâmicos , TrítioRESUMO
The effect of alpha-amino-3-hydroxy-5-methylisoxazolepropionate (AMPA) on Ca(2+)-sensitive, tetrodotoxin (TTX)-insensitive K(+)-stimulated [3H]-L-glutamate release from rat hippocampal synaptosomes was determined. AMPA in the presence, but not in the absence of cyclothiazide, a drug which blocks AMPA receptor desensitization, elicited a dose-dependent increase in K(+)-stimulated [3H]-L-glutamate release but had no effect on basal release. The AMPA/cyclothiazide stimulation was blocked by CNQX and by GYKI 52466, an antagonist at the cyclothiazide site. These results indicate that AMPA receptors are present on presynaptic terminals and suggest that they may play a role in the regulation of neurotransmitter release.
Assuntos
Benzotiadiazinas/farmacologia , Ácido Glutâmico/metabolismo , Hipocampo/metabolismo , Inibidores de Simportadores de Cloreto de Sódio/farmacologia , Sinaptossomos/metabolismo , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiônico/farmacologia , Animais , Benzotiadiazinas/antagonistas & inibidores , Carbacol/farmacologia , Diuréticos , Feminino , Hipocampo/efeitos dos fármacos , Técnicas In Vitro , Potenciação de Longa Duração/efeitos dos fármacos , Potássio/farmacologia , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/metabolismo , Ratos , Ratos Wistar , Inibidores de Simportadores de Cloreto de Sódio/antagonistas & inibidores , Estimulação Química , Sinaptossomos/efeitos dos fármacos , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiônico/antagonistas & inibidoresRESUMO
1. The pharmacological properties of 5-HT3 receptor recognition sites labelled with [3H]-(S)-zacopride, [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330 in membranes prepared from the rat entorhinal cortex were investigated to assess the presence of cooperativity within the 5-HT3 receptor complex. 2. In rat entorhinal cortex homogenates, [3H]-(S)-zacopride, [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330 labelled homogeneous densities of recognition sites (defined by granisetron, 10 microM) with high affinity (Bmax = 75 +/- 5, 53 +/- 5, 92 +/- 6 and 79 +/- 6 fmol mg-1 protein, respectively; pKd = 9.41 +/- 0.04, 8.69 +/- 0.14, 8.81 +/- 0.06 and 10.14 +/- 0.04 for [3H]-(S)-zacopride, [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330, respectively, n = 3-8). 3. Quipazine and granisetron competed for the binding of each of the radioligands in the rat entorhinal cortex preparation at low nanomolar concentrations (pIC50; quipazine 9.38-8.51, granisetron 8.62-8.03), whilst the agonists, 5-hydroxytryptamine (5-HT), phenylbiguanide (PBG) and 2-methyl-5-HT competed at sub-micromolar concentrations (pIC50; 5-HT 7.16-6.42, PBG 7.52-6.40, 2-methyl-5-HT 7.38-6.09). 4. Competition curves generated with increasing concentrations of quipazine, PBG, 5-HT and 2-methyl-5-HT displayed Hill coefficients greater than unity when the 5-HT3 receptor recognition sites in the entorhinal cortex preparation were labelled with [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330. These competing compounds displayed Hill coefficients of around unity when the sites were labelled with [3H]-(S)-zacopride. Competition for the binding of [3H]-(S)-zacopride, [3H]-LY278,584, [3H]-granisetron and [3H]-GR67330 by granisetron generated Hill coefficients around unity.5. The nature of the interaction of competing compounds (quipazine, granisetron, PBG, 5-HT, 2-methyl-5-HT) for the [3H]-(S)-zacopride binding site in the rat entorhinal cortex preparation was not altered by the removal of the Krebs ions or the addition of the monoamine oxidase inhibitor, pargyline, to the HEPES/Krebs buffer.6. In conclusion, the present studies provide further evidence towards the presence of cooperativity within the 5-HT3 receptor macromolecule and indicate that either [3H]-(S)-zacopride labels a different site on the receptor complex from [3H]-LY278,584, [3H]-granisetron or [3H]-GR67330, or it binds in such a manner as to prevent the conformatory change in the receptor protein responsible for the cooperative binding of agonists (and quipazine).
Assuntos
Córtex Cerebral/metabolismo , Receptores de Serotonina/efeitos dos fármacos , Animais , Ligação Competitiva/efeitos dos fármacos , Feminino , Técnicas In Vitro , Cinética , Pargilina/farmacologia , Quipazina/metabolismo , Quipazina/farmacologia , Ensaio Radioligante , Ratos , Antagonistas da Serotonina/metabolismo , Antagonistas da Serotonina/farmacologiaRESUMO
The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands. Competition curves generated with increasing concentrations of 5-HT3 receptor ligands emphasized the pharmacological similarity of the two recognition sites labelled by [3H]-(S)-zacopride and [3H]granisetron. However, analysis of the nature of the competition curves indicated that 5-HT3 receptor agonists (5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, phenylbiguanide) and quipazine generated Hill coefficients greater than unity when the 5-HT3 receptor recognition sites were labelled with [3H]granisetron whilst these competing compounds displayed Hill coefficients of around unity when the sites were labelled with [3H]-(S)-zacopride. Competition for either [3H]-(S)-zacopride or [3H]granisetron binding by the 5-HT3 receptor antagonists granisetron and ondansetron generated Hill coefficients around unity. Furthermore, addition of unlabelled (S)-zacopride (1.0 nM) failed to alter the nature by which quipazine competed for the [3H]granisetron-labelled 5-HT3 receptor recognition site. Consistent with 5-HT3 receptors radiolabelled in rat cortical membranes, the present studies indicate that [3H]-(S)-zacopride may label a different site on the 5-HT3-receptor complex compared to [3H]granisetron.
Assuntos
Benzamidas/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes , Compostos Bicíclicos com Pontes/farmacologia , Glioma/metabolismo , Indazóis/farmacologia , Neuroblastoma/metabolismo , Receptores de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/metabolismo , Animais , Benzamidas/metabolismo , Biguanidas/metabolismo , Sítios de Ligação , Ligação Competitiva , Compostos Bicíclicos com Pontes/metabolismo , Membrana Celular/metabolismo , Membrana Celular/ultraestrutura , Glioma/ultraestrutura , Granisetron , Indazóis/metabolismo , Cinética , Neuroblastoma/ultraestrutura , Ondansetron/metabolismo , Quipazina/metabolismo , Serotonina/metabolismo , Antagonistas da Serotonina , Agonistas do Receptor de Serotonina/farmacologia , TrítioRESUMO
Radiation inactivation analysis was used to estimate the target size of a putative glutamate receptor subtype in goldfish brain. A simple, linear inactivation curve was obtained. The calculated molecular size of the [3H]kainate binding site was 33.8 kDa. The results presented here are comparable to the molecular masses determined for putative glutamate receptors in other lower vertebrates but are markedly different from the sizes of the corresponding glutamate receptor subtypes in mammalian central nervous system.
Assuntos
Química Encefálica , Receptores de Glutamato/química , Animais , Proteínas de Ligação ao GTP/metabolismo , Carpa Dourada , Ácido Caínico/metabolismo , Peso Molecular , Receptores de Ácido Caínico , TrítioRESUMO
The pharmacological characteristics of the high affinity [3H]5-hydroxytryptamine ([3H]5-HT) uptake system were investigated in the cerebral cortex of the rat and guinea-pig. In crude cortical synaptosomal preparations from the rat and guinea-pig, [3H]5-HT accumulated with high affinity (Km, 72 +/- 12 and 57 +/- 14 nM for rat and guinea-pig cortical synaptosomal preparation, respectively, mean +/- SEM, N = 5) and with a comparable maximum activity (Vmax, 1.22 +/- 0.21 and 0.90 +/- 0.19 pmol/min/mg protein for rat and guinea-pig cortical synaptosomal preparation, respectively, mean +/- SEM, N = 5). Competition studies employing a range of structurally diverse competing compounds showed that the [3H]5-HT uptake was pharmacologically similar in both preparations. However, citalopram possessed approximately 10-fold weaker affinity to prevent [3H]5-HT uptake in the guinea-pig preparation when compared to the rat and all of the tricyclic antidepressants assessed in the present studies (amitriptyline, nortriptyline, desipramine and imipramine) displayed higher affinity in the guinea-pig preparation when compared to the rat. It is concluded that the high affinity 5-HT uptake systems in the rat and guinea-pig cortex are similar but may not be identical.
Assuntos
Córtex Cerebral/metabolismo , Serotonina/metabolismo , Amitriptilina/farmacologia , Animais , Ligação Competitiva , Córtex Cerebral/efeitos dos fármacos , Citalopram/farmacologia , Desipramina/farmacologia , Feminino , Cobaias , Cinética , Nortriptilina/farmacologia , Ratos , Sinaptossomos/metabolismoRESUMO
Nine surgical pathologists participated in a microscopic review of 35 cases of pT1-2 N0 M0 breast carcinoma. The pathologists outlined strict criteria for the identification of intramammary lymphatics and blood vessels and for the identification of cancerous emboli in these vascular channels. Each mastectomy case was studied by three different pathologists. All three concurred on the presence or absence of intralymphatic cancer in 12 of the 35 cases. Observers agreed on the absence of blood vessel invasion in 30 of the 35 cases. There was no consistent bias on the part of a single reviewer, either alone or with another pathologist, in identifying the emboli. We conclude that the identification of intralymphatic cancerous emboli in mastectomy specimens is not a reliably reproducible prognostic finding on which recommendation of systemic chemotherapy in stage I breast carcinoma patients can be based.
Assuntos
Neoplasias da Mama/patologia , Sistema Linfático/patologia , Neoplasias da Mama/irrigação sanguínea , Humanos , Patologia Cirúrgica/normasRESUMO
The present study assessed the binding characteristics of [125I]angiotensin II to slices of human cerebellum adhered to glass slides using quantitative receptor autoradiography. Specific [125I]angiotensin II binding, defined by the inclusion of unlabelled angiotensin II (1.0 microM), was detected in the molecular layer of the cerebellum (0.09 +/- 0.02 fmol/mg tissue equivalent, mean +/- s.e.m., n = 3). The angiotensin II-2 receptor subtype selective ligand, PD123177, competed for approximately 65% of the specific binding in the molecular layer whilst the remainder of the specific binding was displaced by the angiotensin II-1 receptor subtype selective ligand, DuP753. It is concluded that angiotensin II receptor subtypes exist in human brain tissue and provide potential therapeutic sites of action.
Assuntos
Angiotensina II/metabolismo , Cerebelo/metabolismo , Receptores de Angiotensina/metabolismo , Idoso , Angiotensina II/antagonistas & inibidores , Antagonistas de Receptores de Angiotensina , Autorradiografia , Ligação Competitiva , Compostos de Bifenilo/farmacologia , Cerebelo/citologia , Feminino , Humanos , Imidazóis/farmacologia , Radioisótopos do Iodo , Losartan , Masculino , Piridinas/farmacologia , Receptores de Angiotensina/análise , Tetrazóis/farmacologiaRESUMO
The binding of a series of [3H]glutamatergic ligands was determined by receptor autoradiography of membrane homogenate pellets and horizontal sections of Xenopus brain. Consistent with previous reports that a 'unitary' glutamate receptor is present in Xenopus CNS, the radioligands showed similar densities of binding sites in the membrane homogenate pellets. Furthermore, [3H]kainate binding was completely displaced by AMPA or CNQX, [3H]AMPA binding was completely displaced by kainate or CNQX and [3H]CNQX binding was completely displaced by AMPA or kainate. However, in whole brain sections there were apparently 2- to 5-fold more [3H]AMPA and [3H]CNQX than [3H]kainate sites. The absence of these extra sites in broken-washed membrane preparations suggests that the additional [3H]AMPA and [3H]CNQX binding may be due to cytosolic sites. The observation that all [3H]AMPA and [3H]CNQX binding in the brain sections is displaced by kainate indicates that the putative cytosolic sites are sensitive to relatively high concentrations of kainate but that they differ from the previously characterised Xenopus CNS unitary receptors.
Assuntos
Receptores de AMPA/análise , Receptores de Glutamato/análise , Animais , Autorradiografia , Química Encefálica/fisiologia , Ensaio Radioligante , Trítio , XenopusRESUMO
Goldfish brain is a widely used model system for the study of the mechanisms involved in neuronal regeneration and synaptic plasticity. Because of the proposed role of glutamate receptors in these processes we have investigated the anatomical localisations of [3H]AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate), [3H]kainate, [3H]CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) and [3H]L-glutamate binding sites in horizontal and sagittal sections. Binding sites for [3H]L-glutamate were the most widespread and both NMDA (N-methyl-D-aspartate) and non-NMDA sensitive components were detected. The density of [3H]kainate binding was very high in the cerebellum compared to other regions and in comparison with the other radioligands used. Conversely, relatively low amounts of [3H]AMPA binding were present with the telencephalon being the most densely labelled structure. [3H]CNQX binding was most densely localised in the tectum with the cerebellum also possessing high binding. In addition, there was a small population of [3H]CNQX binding sites located in the telencephalon and lobus vagi that appeared insensitive to AMPA and kainate.
Assuntos
Química Encefálica/fisiologia , Encéfalo/anatomia & histologia , Carpa Dourada/metabolismo , Receptores de Glutamato/metabolismo , 6-Ciano-7-nitroquinoxalina-2,3-diona , Animais , Autorradiografia , Cinética , Quinoxalinas/farmacocinética , Receptores de AMPA/metabolismo , Receptores de Glutamato/efeitos dos fármacos , Receptores de Ácido Caínico/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismoRESUMO
The effects of angiotensin I and II on basal potassium-induced release of [3H]acetylcholine were investigated in slices of rat entorhinal cortex. Potassium (10-25 mM) produced a concentration-dependent increase in the release of [3H]acetylcholine in the presence of extracellular calcium. Angiotensin II (10(-9)-10(-5) M) (but not angiotensin I) reduced the potassium-induced release of [3H]acetylcholine in a concentration-related manner to 60% of control levels, but did not effect basal tritium release. The effect of angiotensin II was antagonised by [1-sarcosine, 8-threonine] angiotensin II, an angiotensin II receptor antagonist, but not by agents acting on alpha- and beta-adrenoceptors, muscarinic, nicotinic, histamine or 5-hydroxytryptamine receptors nor by the angiotensin converting enzyme (ACE) inhibitor SQ 29852. The results indicate that angiotensin II acting via an angiotensin II receptor can inhibit the release of [3H]acetylcholine in slices of the rat entorhinal cortex. It is hypothesised that the ability of ACE inhibitors to facilitate cognitive processes may be related to a reduced availability of angiotensin II.
Assuntos
Acetilcolina/farmacocinética , Angiotensina II/farmacologia , Córtex Cerebral/metabolismo , Angiotensina II/análogos & derivados , Angiotensina II/antagonistas & inibidores , Animais , Cálcio/fisiologia , Córtex Cerebral/efeitos dos fármacos , Feminino , Técnicas In Vitro , Potássio/farmacologia , RatosRESUMO
Angiotensin II was shown to inhibit potassium-stimulated release of [3H]acetylcholine from slices of fresh human temporal cortex, obtained at surgery, and subsequently loaded with [3H]choline for the biochemical analyses. The inhibitory effect of angiotensin II was antagonised by the specific angiotensin II receptor antagonist [1-sarcosine, 8-threonine]-angiotensin II. High affinity binding sites were identified in the human temporal cortex using [125I]angiotensin II, and may provide the functional site of action of angiotensin II to modify [3H]acetylcholine release.
Assuntos
Acetilcolina/farmacocinética , Angiotensina II/farmacologia , Cognição/fisiologia , Lobo Temporal/metabolismo , Acetilcolina/fisiologia , Angiotensina II/análogos & derivados , Angiotensina II/antagonistas & inibidores , Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Feminino , Humanos , Técnicas In Vitro , Pessoa de Meia-Idade , Receptores de Angiotensina/metabolismo , Lobo Temporal/efeitos dos fármacos , Lobo Temporal/fisiologiaRESUMO
Increasing evidence indicates that the 5-HT3 receptor antagonist R(+)-zacopride labels an additional site in brain tissue that is not sensitive to 5-HT (non-5-HT R(+)-zacopride site, R(+)-site). Since the levels of R(+)-sites in the brain are relatively low, the present studies explored the use of [125I]R(+)-zacopride to label the R(+)-site; the incorporation of an [125I] atom considerably increasing the specific activity of the radioligand relative to [3H]R(+)-zacopride that has been utilised previously. Competition experiments with [125I]R(+)-zacopride (1.0 nM) binding to rat whole brain homogenates, in the presence of the 5-HT3 receptor antagonist granisetron (1.0 microM), identified that R(+)-zacopride and prazosin bound to two sites (pIC50: 7.59 and 5.28, respectively, for R(+)-zacopride; 6.75 and 4.42, respectively, for prazosin) whereas S(-)-zacopride and mianserin possessed relatively low affinity (pIC50: 4.37 and 3.80, respectively) while (-)sulpiride and 5-HT failed to compete for [125I]R(+)-zacopride binding at concentrations up to 10 microM. Autoradiographic radioligand binding studies using [125I]R(+)-zacopride (0.5 nM) identified a heterogeneous distribution of specific binding sites (defined by unlabelled R(+)-zacopride, 1.0 microM) throughout the rat brain. In the presence of a saturating concentration of granisetron (1.0 microM), highest levels of specific [125I]R(+)-zacopride, binding sites (defined by R(+)-zacopride, 1.0 microM; R(+)-site), were detected in the olfactory tubercle, thalamus, corpus callosum, colliculus, dorsal and median raphe nucleus, spinal cord and the pons (8.0-13.0 fmol/mg). Moderate densities of R(+)-sites were located in the striatum, nucleus accumbens, substantia nigra, ventral tegmental area, globus pallidus, septal nuclei, frontal cortex and cerebellum (2.0-7.9 fmol/mg). In the hippocampus, amygdala and cortical areas. R(+)-site levels were low but detectable (0.1-1.9 fmol/mg). [125I]R(+)-zacopride labelled R(+)-sites were also detected in some rat peripheral tissues, for instance kidney cortex, adrenal gland and liver (2.4-6.8 fmol/mg). The present results indicate that specific non-5-HT [125I]R(+)-zacopride sites are heterogeneously distributed throughout the rat brain and are expressed in various peripheral tissues.
Assuntos
Benzamidas/metabolismo , Encéfalo/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes/metabolismo , Antagonistas da Serotonina/metabolismo , Animais , Autorradiografia , Ligação Competitiva , Técnicas In Vitro , Radioisótopos do Iodo , Masculino , Mianserina/metabolismo , Prazosina/metabolismo , Ligação Proteica , Ensaio Radioligante , Ratos , Ratos Wistar , Receptores de Serotonina/metabolismo , Receptores 5-HT3 de Serotonina , Serotonina/metabolismo , Estereoisomerismo , Sulpirida/metabolismo , Distribuição TecidualRESUMO
Autoradiographic and homogenate binding studies using the radioligand, [125I]angiotensin II, identified a heterogeneous distribution of specific binding sites (defined by angiotensin II, 1.0 microM) throughout the human forebrain. Highest AT receptor densities were detected in the paraventricular nucleus, median eminence, substantia nigra, putamen and caudate nucleus (2.4, 1.2, 1.0, 0.30 and 0.24 fmol/mg tissue equivalent, respectively). The AT1 receptor antagonist, losartan (1.0 microM) competed for the majority of the specific binding. [125I]Angiotensin II-specific binding (although not consistently above non-specific binding levels) was also detected in various other brain regions (e.g. amygdala, entorhinal cortex, frontal cortex, hippocampus, inferior colliculus, nucleus accumbens, parietal cortex, periaquaductal grey, superior colliculus, striate cortex, temporal cortex, thalamus). In the presence of losartan (1.0 microM), angiotensin II, saralasin, losartan and PD123177 competed for [125I]angiotensin II binding to membranes prepared from the cerebellum or substantia nigra with a rank order of affinity; angiotensin II = saralasin > PD123177 > losartan. In the presence of PD123177 (1.0 microM), the rank order of affinity of losartan and PD123177 was reversed. These studies indicate the presence of both AT1 and AT2 receptor subtypes within various regions of the human forebrain.
Assuntos
Química Encefálica , Receptores de Angiotensina/análise , Idoso , Angiotensina II/farmacologia , Antagonistas de Receptores de Angiotensina , Autorradiografia , Ligação Competitiva , Compostos de Bifenilo/farmacologia , Feminino , Humanos , Imidazóis/farmacologia , Técnicas In Vitro , Radioisótopos do Iodo , Losartan , Masculino , Pessoa de Meia-Idade , Piridinas/farmacologia , Ensaio Radioligante , Saralasina/farmacologia , Tetrazóis/farmacologiaRESUMO
The present studies demonstrate the presence of specific [3H]GR65630 binding sites within the human brainstem using the techniques of in vitro receptor autoradiography and ligand binding to homogenates. Autoradiography revealed the greatest accumulation of specific binding in the area postrema and subpostrema (AP/ASP). A lower level of specific binding was identified in the nucleus tractus solitarius (excluding area subpostrema). No specific binding was evident in the remainder of the hindbrain at this level. Discrete dissection followed by ligand binding to homogenates revealed that the specific binding of [3H]GR65630 (defined by the presence of 30 microM metoclopramide) was differentially distributed with highest levels in the AP/ASP (112.1 fmol/mg protein) and lower levels in the dorsal vagal complex (nucleus tractus solitarius--excluding the area subpostrema--dorsal motor nucleus of the vagus and hypoglossal nucleus) (DVC) and olivary nucleus (ON) (22.9 and 3.9 fmol/mg, respectively). No specific binding was detectable in the reticular formation (RF) located ventral to the dorsal vagal complex. The specific [3H]GR65630 binding site was pharmacologically similar to the 5-HT3 receptor since the potent and selective 5-HT3 receptor antagonists ICS 205-930 and zacopride (100 nM) and the agonist 5-HT (10 microM) inhibited binding to the same extent as metoclopramide in each of the individual areas (90, 60 and 20% in the AP/ASP, DVC and ON, respectively). The 5-HT1-like and 5-HT2 receptor antagonist methysergide (10 microM) failed to compete for the binding site. 5-HT3 receptor recognition sites within the AP/ASP and the DVC may be functionally involved in the ability of 5-HT3 receptor antagonists to control emesis.
Assuntos
Tronco Encefálico/metabolismo , Imidazóis/metabolismo , Indóis/metabolismo , Receptores de Serotonina/metabolismo , Adulto , Idoso , Ligação Competitiva , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas da SerotoninaRESUMO
Autoradiographic binding studies using the 5-HT3 (5-hydroxytryptamine3) receptor radioligand, [3H]-(S)-zacopride (0.5 nM), identified a heterogeneous distribution of specific binding sites (defined by granisetron, 1 microM) throughout the human brain. Highest radiolabelled 5-HT3 receptor densities were detected in discrete nuclei within the brainstem (nucleus tractus solitarius, area postrema, spinal trigeminal nerve nucleus; 50-200 fmol/mg tissue equivalent) with more modest levels of expression in the forebrain (e.g. hippocampus, nucleus accumbens, putamen, caudate; 4-17 fmol/mg tissue equivalent). Within the hippocampal formation, radiolabelled 5-HT3 receptors were differentially distributed with highest levels in the granule cell layer of the dentate gyrus. Saturation studies with [3H]-(S)-zacopride (0.05-16 nM; non-specific binding defined by granisetron, 10 microM) binding to homogenates of human putamen indicated that [3H]-(S)-zacopride (0.05-16 nM; non-specific binding defined by granisetron, 10 microM) binding to homogenates of human putamen indicated that [3H]-(S)-zacopride labelled an apparently homogenous population of binding sites (Bmax = 72 + 7 fmol mg-1 protein, pKd = 8.69 +/- 0.09, Hill coefficient = 0.99 +/- 0.06, mean +/- SEM, n = 4). The pharmacological profile of [3H]-(S)-zacopride binding to homogenates of putamen indicated the selective labelling of the human variant of the 5-HT3 receptor. The marked differences, however, in the pharmacology (e.g. low affinity for D-tubocurarine) and relative distribution (e.g. presence of 5-HT3 receptors in the human extrapyramidal system) of 5-HT3 receptors in the human forebrain when compared with other species further necessitates caution in predicting clinical responses based on data generated in animal models of disease.